But of Course, Ocata is at Bankruptcy's DoorstepROTFLOL
Two Moons KA-CHING !!!
I've come to thinking that there is no 'reason'
for any single day's action in a share's price.
But look back at a 5 year chart, and the number
6 jumps out as a sort of baseline price for Ocata.
And that's what has happened. A gigantic base
has been built it this stock. The old rule of thumb
applies here: The greater the base, the higher
the race.
When this stock takes off you can take that base
on the chart and turn it vertical 90 degrees to
get an idea how high Ocata's share price will go.
These charts are logarithmic.
The first milestones for the share price are
the 8.39 and 12.73 tops. After it blows through
28.00, it will go parabolic.
Post Successful phase 1, and soon when
phase 2 AMD has begun, we will see
many days like today.
Really, when that first phase 2 AMD patient is
injected, six months later, Ocata's story will
be finishing act II.
PW_CC_12mar15(edited)
Our number one corporate objective for 2015 is the
initiation of the next phase of our clinical trials.
Act III, will be the build out of a tiny company
into something like the Apple of a new
healthcare system, a few years down wind.
It's the nature of technology. New technologies
cannot be stopped. Problems will arise, only
to be solved again, and again.
Nothing stops technology, not wars, not economic
crashes, not widespread ignorance. You can plot
the rise of any particular technology on a chart
over time.
Ocata is the BEGINNING of Stem Cell Technology.
Their first therapy is RPE tissue transplantation.
But it's the first of MANY to come.
RPE is the focal point right now. But behind this
point is an enormous Intellectual Property base
that provides a rock solid foundation.
Comments From the CC 12Mar2015
PW_CC_12mar15(edited)
Our number one corporate objective for 2015 is the initiation of the next phase of our clinical trials.
We plan to initiate our Phase II trial for dry AMD in the second quarter of this[2015] year.
This Phase II study will include up to three cohorts of approximately 20 patients each.
We intend to complete the first cohort dosing during 2015.
Each of the three cohorts will be treated with a different immune suppression regimen to determine how much, if any, immune suppression is required.
PW_CC_12mar15(end)
